Staccato Loxapine Pulmonary Safety in Patients With Asthma

Completed · Phase 1 · Has a placebo group

Conditions studied: Asthma

In brief

The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.

Key facts

Study ID

NCT00890175

Run by

Alexza Pharmaceuticals, Inc.

People needed

52

Starts

2009-05-01

Expected to finish

2009-08-01

Last updated by the study team

2017-03-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• History of mild to moderate persistent asthma for at least 6 months with pre-bronchodilator FEV1 ≥60% of predicted value.

You may not qualify if…

• History of COPD, or any other acute or chronic pulmonary disease

Where it is running

• Allergy and Asthma Medical Group & Research Center, A.P.C. — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.